Tibulizumab
Sponsors
Zura Bio Inc., Zura Bio Inc
Conditions
Hidradenitis SuppurativaSclerodermaSystemic SclerosisSystemic Sclerosis (SSc)
Phase 2
Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)
Active, not recruitingNCT06843239
Start: 2025-02-06End: 2028-01-01Target: 80Updated: 2026-07-20
A phase 2, multi-center study consisting of a randomized, placebo-controlled period, followed by an open-label extension period to assess the efficacy, safety, and tolerability of tibulizumab in adults with hidradenitis suppurativa
RecruitingCTIS2024-519736-17-00
Start: 2025-10-03Target: 90Updated: 2025-12-17
A Phase 2, Multi-Center Study Consisting of a Randomized, Double-Blind, Placebo-Controlled Period, Followed by an Open-Label Extension Period, to Assess the Efficacy, Safety, and Tolerability of Tibulizumab in Adults with Systemic Sclerosis
RecruitingCTIS2024-519335-42-01
Start: 2025-12-22Target: 37Updated: 2025-12-19